Patents by Inventor Yongchun Pan

Yongchun Pan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bipyrazole derivatives as JAK inhibitors
    Patent number: 11905275
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: January 24, 2023
    Date of Patent: February 20, 2024
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • Process and intermediates for preparing a JAK inhibitor
    Patent number: 11905292
    Abstract: The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.
    Type: Grant
    Filed: August 17, 2021
    Date of Patent: February 20, 2024
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, James M. Parks, Yongchun Pan, Naijing Su, Michael Xia, Weiguo Liu
  • Process and intermediates for preparing a JAK1 inhibitor
    Patent number: 11897889
    Abstract: The present invention is related to processes for preparing itacitinib, or a salt thereof, and related synthetic intermediates related thereto.
    Type: Grant
    Filed: August 17, 2021
    Date of Patent: February 13, 2024
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, Yongchun Pan, Naijing Su, Michael Xia
  • PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR
    Publication number: 20230406852
    Abstract: The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: August 31, 2023
    Publication date: December 21, 2023
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Yi Li, Qiyan Lin, Pingli Liu, Yongchun Pan, Timothy Martin, Bo Shen, Chongsheng Eric Shi, Naijing Su, Yongzhong Wu, Michael Xia
  • SOLID FORMS OF JAK INHIBITOR AND PROCESS OF PREPARING THE SAME
    Publication number: 20230399331
    Abstract: The present disclosure is related to solid forms of ruxolitinib di-hydrate and ruxolitinib free base, process of preparing the same, and compositions comprising the same.
    Type: Application
    Filed: June 14, 2023
    Publication date: December 14, 2023
    Inventors: Zhongjiang Jia, Weiguo Liu, Pingli Liu, David Meloni, Yongchun Pan, Jiacheng Zhou, Travis Houston
  • Process of preparing a PD-1/PD-L1 inhibitor
    Patent number: 11780836
    Abstract: The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: October 10, 2023
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Yi Li, Qiyan Lin, Pingli Liu, Yongchun Pan, Timothy Martin, Bo Shen, Chongsheng Eric Shi, Naijing Su, Yongzhong Wu, Michael Xia
  • Crystalline form of a PD-1/PD-L1 inhibitor
    Patent number: 11760756
    Abstract: The present invention relates to crystalline forms of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, including methods of preparation thereof, and related synthetic intermediates, where the compound is useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: September 19, 2023
    Assignee: Incyte Corporation
    Inventors: Zhongjiang Jia, Shili Chen, Mei Li, Pingli Liu, Yongchun Pan, Yongzhong Wu, Jiacheng Zhou
  • Salts of a PD-1/PD-L1 inhibitor
    Patent number: 11753406
    Abstract: The present invention relates to salt forms of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, including methods of preparation thereof, where the compound is useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: September 12, 2023
    Assignee: Incyte Corporation
    Inventors: Zhongjiang Jia, Pingli Liu, David J. Meloni, Yongchun Pan, Yongzhong Wu, Jiacheng Zhou, Qun Li
  • Processes of preparing a JAK1 inhibitor
    Patent number: 11685731
    Abstract: The present application provides processes for preparing 4-[3-(cyanomethyl)-3-(3?,5?-dimethyl-1H, 1?H-4,4?-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, and phosphoric acid salt thereof, which is useful as a selective (Janus kinase 1) JAK1 inhibitor, as well as salt forms and intermediates related thereto.
    Type: Grant
    Filed: June 2, 2021
    Date of Patent: June 27, 2023
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Yingrui Dai, Zhongjiang Jia, Yongchun Pan, James M. Parks, Anthony J. Tomaine, Jianji Wang, Aibin Zhang
  • BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20230159501
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: January 24, 2023
    Publication date: May 25, 2023
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • SALTS OF A PIM KINASE INHIBITOR
    Publication number: 20230111912
    Abstract: The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
    Type: Application
    Filed: November 7, 2022
    Publication date: April 13, 2023
    Inventors: Zhongjiang Jia, Ganfeng Cao, Qiyan Lin, Yongchun Pan, Lei Qiao, Vaqar Sharief, Chongsheng Eric Shi, Michael Xia, Changsheng Zheng, Jiacheng Zhou, Qun Li
  • SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME
    Publication number: 20230098850
    Abstract: The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.
    Type: Application
    Filed: August 18, 2022
    Publication date: March 30, 2023
    Inventors: Lingkai Weng, Lei Qiao, Jiacheng Zhou, Pingli Liu, Yongchun Pan
  • Bipyrazole derivatives as JAK inhibitors
    Patent number: 11591318
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: February 28, 2023
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR
    Publication number: 20230059389
    Abstract: The present disclosure is related to processes for preparing baricitinib, salts thereof, and related synthetic intermediate compounds and salts thereof.
    Type: Application
    Filed: July 11, 2022
    Publication date: February 23, 2023
    Inventors: Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Pingli Liu, David Meloni, Yongchun Pan, Naijing Su, Michael Xia
  • Salts of an LSD1 inhibitor and processes for preparing the same
    Patent number: 11512064
    Abstract: The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate demethylase. Particular embodiments contemplate compounds and disease indications amenable to treatment by modulation of lysine specific demethylase-1 (LSD1).
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: November 29, 2022
    Assignee: Incyte Corporation
    Inventors: Zhongjiang Jia, Wayne Han, Yongchun Pan, Timothy Martin, Jiacheng Zhou, Qun Li
  • Salts of a Pim kinase inhibitor
    Patent number: 11505540
    Abstract: The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: November 22, 2022
    Assignee: Incyte Corporation
    Inventors: Zhongjiang Jia, Ganfeng Cao, Qiyan Lin, Yongchun Pan, Lei Qiao, Vaqar Sharief, Chongsheng Eric Shi, Michael Xia, Changsheng Zheng, Qun Li
  • Salts of an LSD1 inhibitor
    Patent number: 11498900
    Abstract: The present disclosure relates to tosylate salts 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the LSD1-associated or mediated diseases such as cancer.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: November 15, 2022
    Assignee: Incyte Corporation
    Inventors: Yongchun Pan, Wayne Han, Ganfeng Cao, Zhongjiang Jia, Jiacheng Zhou
  • Crystalline forms of a FGFR inhibitor and processes for preparing the same
    Patent number: 11472801
    Abstract: The present disclosure relates to solid forms of N-{[2?-(2,6-difluoro-3,5-dimethoxyphenyl)-3?-oxo-2?,3?-dihydro-1?H-spiro[cyclopropane-1,4?-[2,7]naphthyridin]-6?-yl]methyl}acrylamide, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: October 18, 2022
    Assignee: Incyte Corporation
    Inventors: Yongchun Pan, Chongsheng Eric Shi, Ming Tao, Wayne Han, Michael Xia, Dengjin Wang, Zhongjiang Jia, Jiacheng Zhou, Qun Li
  • Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
    Patent number: 11452726
    Abstract: The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: September 27, 2022
    Assignees: Incyte Corporation, Inctye Holdings Corporation
    Inventors: Lingkai Weng, Lei Qiao, Jiacheng Zhou, Pingli Liu, Yongchun Pan
  • SALTS OF TAM INHIBITORS
    Publication number: 20220227770
    Abstract: The present application provides salt forms of N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide and N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which are useful as inhibitors of TAM kinases, as well as processes and intermediates related thereto.
    Type: Application
    Filed: August 13, 2021
    Publication date: July 21, 2022
    Inventors: Zhongjiang Jia, Yongzhong Wu, Yongchun Pan, Jiacheng Zhou, Qun Li